Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




More Heparin Recalls in Europe and US
Link ID 4252
Title More Heparin Recalls in Europe and US
Url http://www.medscape.com/viewarticle/571965?src=rss
Description The latest countries to recall heparin products are France, Italy, and Denmark, and the affected material has been traced to four Chinese suppliers. Another US manufacturer has also recalled some heparin products. Heartwire
Category Articles > Business of Medicine
Keywords
Date Mar 26, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. Cost Sharing Deters Mammography, Putting Women at Risk, Study Finds
  Even small copayments led to significantly lower mammography rates among women who, according to clinical guidelines, should undergo screening. Medscape Medical News
Category:   Articles > Business of Medicine


2. Scramble to Screen: Hospitalist Groups Revamp Admission Assessments Before Medicare Rules for Reimbu
  Medicare will begin denying reimbursement for certain conditions if they are acquired in the hospital. How are hospitalist groups refining their screening methods and what are the challenges?
The Hospitalist
Category:   Articles > Business of Medicine


3. McCain Would Hike Drug Costs for Wealthy Americans
  U.S. Republican presidential candidate John McCain will outline economic proposals on Tuesday that would increase drug costs for wealthy seniors and freeze billions in government spending for a year. Reuters Health Information
Category:   Articles > Business of Medicine


4. Rite Aid Says Chief Marketing Officer to Leave
  Drugstore chain Rite Aid Corp said Mark Panzer, senior executive vice president and chief marketing officer, will leave the company. Reuters Health Information
Category:   Articles > Business of Medicine


5. Tarenflurbil Fails to Meet Primary End Point in Phase 3; End of the Road for Development
  In a brief statement, Myriad Genetics reports that tarenflurbil failed to have a significant effect in mild AD patients in a phase 3 trial and announced that it will not continue development of the compound. Medscape Medical News
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS